Enlivex up on positive Allocetra results in COVID-19

• Enlivex Therapeutics (NASDAQ:ENLV) reports positive top line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition.
• The trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients were released from the hospital after an average of 5.5 days (severe) and 8.5 days (critical), following administration of Allocetra, at which time they were all COVID-19 PCR negative.
• There were no reported severe adverse events, and the therapy was well-tolerated.
• The company has determined to shift recruitment of additional patients from the investigator-initiated clinical trial into a larger Phase II clinical trial of COVID-19 patients based on the positive results of the first five COVID-19 patients together with the positive safety and efficacy results of Allocetra in 10 sepsis patients in a previous study.
• The planned Phase IIb trial is expected to commence in Q4.
• https://seekingalpha.com/news/3618709-enlivexplus-5-on-positive-allocetra-results-in-covidminus-19